Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Puma Biotechnology revises Neratinib licensing deal with Pfizer
Currently, Puma is developing PB272 for the treatment of patients with HER2-positive breast cancer as well as for patients with non-small cell lung cancer, breast cancer and other
Currently, Puma is developing PB272 for the treatment of patients with HER2-positive breast cancer as well as for patients with non-small cell lung cancer, breast cancer and other
Under the deal, CALOX will be responsible for securing regulatory and pricing approval, as well as the marketing and supply of the medication, in countries including Colombia, Costa
The company said that patients enrolled in the trial must have a documented diagnosis of hypogonadism, or testosterone deficiency defined as having testosterone levels below 300ng/dL. About 150
In 2010, the US Food and Drug Administration (FDA) had approved Zuplenz for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and
The ubiquitin system alterations are related to many common diseases, including cancer, diabetes, inflammation and several central nervous system (CNS) disorders. Scientists from Boehringer and the Toronto academic
Presently, there are no antibiotics, systemic or topical, which are specifically approved by the US Food and Drug Administration (FDA) to treat patients with Mild DFI. FDA has
The company develops new drug candidates to treat Alzheimer’s disease (AD), other diseases of the central nervous system (CNS) and various types of cancer. Anavex president and chief
As part of the deal, Abic secured rights to market and distribute BELVIQ in Israel for weight loss or weight management in obese and overweight patients, subject to
RG-012 binds to and inhibits the function of microRNA-21 (miR-21), as a therapeutic to treat Alport syndrome, a genetic kidney disease. In the near term, the company intends
Avanir intends to start the trial by evaluating AVP-786 for the adjunctive treatment of major depressive disorder (MDD) during the third quarter of 2014. Avanir Pharmaceuticals chief medical